Publishing the results of the estrogen-only arm of WHI

Climacteric

Volumn 7, Issue 2, 2004, Pages 117-119

  MacLennan, Alastair ^a   Sturdee, David W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN; HORMONE;

ALTERNATIVE MEDICINE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR RISK; COLORECTAL CANCER; CONSULTATION; DRUG EFFICACY; DRUG USE; EDITORIAL; ENDOMETRIUM CANCER; EPIDEMIOLOGICAL DATA; ESTROGEN THERAPY; FRAGILITY FRACTURE; HEALTH; HORMONAL THERAPY; HUMAN; HYSTERECTOMY; INTESTINE CANCER; LONG TERM CARE; MASS MEDIUM; MENOPAUSE; METHODOLOGY; ORGANIZATION; OSTEOPOROSIS; OVARIECTOMY; PRIORITY JOURNAL; PUBLICATION; QUALITY OF LIFE; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; VASCULAR DISEASE;

BIAS (EPIDEMIOLOGY); COMMUNICATIONS MEDIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTHY PEOPLE PROGRAMS; HUMANS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; UNITED STATES;

EID: 3242730114     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130410001713706     Document Type: Editorial

References (13)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-33
2. Shapiro S. Risks of estrogen plus progestin therapy: a sensitivity analysis of findings in the Women's Health Initiative randomized controlled trial. Climacteric 2003;6:302-10
3. Ettinger B, Grady D, Tosteson ANA, Pressman A, Macer JL. Effects of Women's Health Initiative on women's decision to discontinue postmenopausal hormone therapy. Obstet Gynecol 2003;102:1225-32
4. MacLennan AH, Taylor AW, Wilson DH. Hormone therapy use after the Women's Health Initiative. Climacteric 2004;7:138-42
5. Paine JP, Stocks NP, Ramsay EN, Ryan P, MacLennan AH. Use and perception of hormone therapy following media reports of the Women's Health Initiative: survey of Australian WISDOM participants. Climacteric 2004;7:143-52
6. Yates J, Barrett-Connor E, Barlas S, Chen Y, Miller PD, Siris ES. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstet Gynecol 2004;103:440-6
7. Creasman WT, Hoel DH, DiSara PJ. WHI: now that the dust has settled. Am J Obstet Gynecol 2003;189:621-6
8. Sturdee D, MacLennan AH. Should epidemiology, the media and quangos determine clinical practice? Climacteric 2004;7:1-2
9. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
10. Vickers M, Meade T, Darbyshire J. WISDOM: history and early demise - was it inevitable? Climacteric 2002;5:317-25
11. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestogen and the risk of coronary heart disease. N Engl J Med 2003;349:532-4
12. Thomas T, Rhodin J, Clark L, Garces A. Progestins initiate adverse events of menopausal estrogen therapy. Climacteric 2003;6:293-301
13. MacLennan AH, MacLennan A, Wilson D. The prevalence of oestrogen replacement therapy in South Australia. Maturitas 1993;16:175-83